Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - fluorescein sodium - eye drops - 10mg/1ml

Velika Britanija - angleščina - MHRA (Medicines & Healthcare Products Regulatory Agency)

bausch & lomb uk ltd - fluorescein sodium - eye drops - 20mg/1ml

Irska - angleščina - HPRA (Health Products Regulatory Authority)

chauvin pharmaceuticals limited - fluorescein sodium - eye drops solution - 1 %w/v

Irska - angleščina - HPRA (Health Products Regulatory Authority)

chauvin pharmaceuticals limited - fluorescein sodium - eye drops solution - 2.0 %w/v

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

bausch & lomb (nz) ltd - fluorescein sodium 1%;   - eye drops, solution - 1 % - active: fluorescein sodium 1%   excipient: purified water

Nova Zelandija - angleščina - Medsafe (Medicines Safety Authority)

bausch & lomb (nz) ltd - fluorescein sodium 2%;   - eye drops, solution - 2 % - active: fluorescein sodium 2%   excipient: purified water

Združene države Amerike - angleščina - NLM (National Library of Medicine)

a-s medication solutions - fluorescein sodium (unii: 93x55pe38x) (fluorescein - unii:tpy09g7xir) - ak-fluor® 10% (100 mg/ml) and 25% (250 mg/ml) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. ak-fluor® is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. rare cases of death due to anaphylaxis have been reported [see warnings and precautions (5.1) and adverse reactions (6.2) ]. pregnancy category c. adequate animal reproduction studies have not been conducted with fluorescein sodium. it is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. fluorescein sodium should be given to a pregnant woman only if clearly needed. fluorescein sodium has been demonstrated to be excreted in human milk. caution should be exercised when fluorescein sodium is administered to a nursing woman. pediatric patients have been included in clinical studies. no overall differences in safety or effectiveness have been observed between pediatric and adult patient

Irska - angleščina - HPRA (Health Products Regulatory Authority)

bausch & lomb uk limited - lignocaine hydrochloride; fluorescein sodium - eye drops, solution - 4.0/0.25 % percent weight/volume - colouring agents; fluorescein, combinations

Kanada - angleščina - Health Canada

bausch & lomb inc - fluorescein sodium - drops - 2% - fluorescein sodium 2% - ocular disorders

Združene države Amerike - angleščina - NLM (National Library of Medicine)

nexus pharmaceuticals llc - fluorescein (unii: tpy09g7xir) (fluorescein - unii:tpy09g7xir) - fluoresecin injection 10%, , (100 mg/ml) and fluorescein injection 25% (250 mg/ml) is indicated in diagnostic fluorescein angiography or angioscopy of the retina and iris vasculature. fluorescein injection, usp is contraindicated in patients with known hypersensitivity to fluorescein sodium or any other ingredients in this product. rare cases of death due to anaphylaxis have been reported [see warnings and precautions (5.1) and adverse reactions (6.2)] . pregnancy category c. adequate animal reproduction studies have not been conducted with fluorescein sodium. it is also not known whether fluorescein sodium can cause fetal harm when administered to a pregnant woman. fluorescein sodium should be given to a pregnant woman only if clearly needed. fluorescein sodium has been demonstrated to be excreted in human milk. caution should be exercised when fluorescein sodium is administered to a nursing woman. pediatric patients have been included in clinical studies. no overall differences in safety or effectiveness ha